Tap Pharmaceuticals had an unethical culture focused on short-term financial profits over ethical responsibilities. This led to unethical business practices like bribing doctors to increase drug sales. Key players like the VP of Sales and sales representatives promoted these practices for personal gain while harming patients and other stakeholders. The document analyzes alternatives for Tap to become more ethically responsible in areas like management alignment, legal oversight of marketing, and consideration of foreign business cultures during global expansion. Recommendations include minimizing harm, respecting local cultures, and paying fair taxes when operating globally.